Grünenthal licenses exclusive Australian rights to Qutenza® to Clinect24.2.2026 09:40:40 EET | Grünenthal Group | Press release
Aachen, Germany & Victoria, Australia, 24 February 2026 – Grünenthal, a global leader in pain management and related diseases, and Clinect Pty Ltd ("Clinect"), an Australian based company focussed on supporting access to unique products, announced today that they have entered into a definitive agreement whereby Clinect will have the exclusive Australian rights to Qutenza®, a topical, non-systemic, non-opioid patch indicated for the management of peripheral neuropathic pain. Under the agreement, Clinect will be responsible for obtaining marketing authorisation for Qutenza® in Australia and, upon approval, marketing and distributing the product in Australia. "We firmly believe in the benefits that this non-opioid treatment option can provide to people suffering from peripheral neuropathic pain and continue to work on expanding its footprint to reach more patients worldwide," says Jan Adams, Chief Commercial Officer (CCO) at Grünenthal. "Clinect is an experienced specialist with a strong